Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson(Prince of Wales Hospital), Ann‐Lii Cheng(National Taiwan University), Won Young Tak(Kyungpook National University Hospital), Ligong Lu(Tongji University), Yee Chao(National Cancer Center), Masatoshi Kudo(Kindai University), Kwang‐Hyub Han(Yonsei University), Shukui Qin(81th Hospital of PLA), Jeong Heo(National Cancer Center), Tsung‐Hui Hu(National Sun Yat-sen University), Éveline Boucher(Boston Scientific (United States)), Rana Ezzeddine(Institut Claudius Regaud), Thomas Decaens(Centre National de la Recherche Scientifique), Jorge Alberto Robles-Aviña(National Cancer Center), Seung Woon Paik(National Cancer Center), Abhasnee Sobhonslidsuk(National Cancer Center), Jean‐Luc Raoul(Institut de Cancérologie de l'Ouest), Д. В. Комов(National Cancer Center), Chih‐Hung Hsu(National Taiwan University of Science and Technology), Jianming Xu(Chinese PLA General Hospital), David Liu(Bristol-Myers Squibb (Germany)), Long‐Bin Jeng(National Cancer Center), Ian Walters(Bristol-Myers Squibb (Germany)), Ronnie T.P. Poon(University of Hong Kong), Joong‐Won Park(National Cancer Center), Lünan Yan(National Cancer Center), Philip A. Philip(Wayne State University)
Cited by 775
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k